Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be ...

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 82c near $32.23. Options volume roughly in line with average with 81k ...

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.

From optimizing healthcare resource utilization to streamlining medical records and patient data management, the Medical Information Systems industry continues to broaden its scope at a rapid pace.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $105.0 for Hims & Hers Health, spanning the last three ...

Hims & Hers compounded GLP-1 — the same ingredient as Ozempic — will be priced at $200 a month. Investors are loving the announcement.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Digital health and wellness company Hims & Hers is investing more than $200 million to expand its operations in New Albany ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...